Adding Hydroxycarbamide to Aspirin of Little Benefit to Certain Older Patients with Essential Thrombocythemia

A recent open-label, randomized trial of patients with essential thrombocythemia age 40-59 without high-risk features or extreme thrombocytosis found that the cytoreductive therapy combination of hydroxycarbamide plus aspirin did not reduce vascular events, myelofibrotic transformation, or leukemic transformation compared with aspirin alone.

Oncology Learning Network